Programmed death 1 receptor changes ex vivo in hiv-infected adults following initiation of highly active antiretroviral therapy

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 752-756

  Spitsin, Sergei ^a   Tustin, Nancy B ^a   Riedel, Eric ^a   Tustin III, Richard ^a   Murray, Jennifer B ^a   Peck, Lauren M ^a   Khan, Mohammad ^a   Quinn, Joseph ^b   Douglas, Steven D ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ATAZANAVIR; CANDIDA ANTIGEN; DARUNAVIR; EMTRICITABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PHYTOHEMAGGLUTININ; PROGRAMMED DEATH 1 RECEPTOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SHORT COURSE THERAPY; TH1 CELL; TH2 CELL; TREATMENT DURATION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIGENS, FUNGAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDA; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; VIRAL LOAD;

EID: 84860340187     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00093-12     Document Type: Article

References (27)

1. + T cell homeostasis and function in advanced HIV disease. Science 277:112-116. (Pubitemid 27450659)
2. Barber DL, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687. (Pubitemid 43237609)
3. Campbell DE, et al. 2009. Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes. Clin. Vaccine Immunol. 16:1648-1653.
4. + T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr. Opin. Immunol. 13:483-488. (Pubitemid 32728483)
5. Chen L, et al. 2007. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 178:6634-6641. (Pubitemid 46717448)
6. Curiel TJ, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-567. (Pubitemid 36597102)
7. Day CL, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354. (Pubitemid 44435155)
8. Douglas SD, et al. 2003. TH1 and TH2 cytokine mRNA and protein levels in human immunodeficiency virus (HIV)-seropositive and HIVseronegative youths. Clin. Diagn. Lab. Immunol. 10:399-404. (Pubitemid 36592966)
9. Fournier S, et al. 2001. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J. Infect. Dis. 183:1586-1591. (Pubitemid 32466695)
10. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203:2223-2227. (Pubitemid 44498355)
11. Grabmeier-Pfistershammer K, Steinberger P, Rieger A, Leitner J, Kohrgruber N. 2011. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J. Acquir. Immune Defic. Syndr. 56:118-124.
12. Han J, et al. 2009. CD14(high)CD16(+) rather than CD14(low) CD16(+) monocytes correlate with disease progression in chronic HIVinfected patients. J. Acquir. Immune Defic. Syndr. 52:553-559.
13. Holm M, Pettersen FO, Kvale D. 2008. PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. Curr. HIV Res. 6:49-58. (Pubitemid 351461021)
14. + cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 48:787-794.
15. Lederman MM, et al. 1998. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J. Infect. Dis. 178:70-79. (Pubitemid 28328078)
16. Nakanjako D, et al. 2008. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: Frequency and clinical significance. AIDS Res. Ther. 5:23.
17. Okazaki T, Honjo T. 2006. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27:195-201.
18. Osakwe CE. 2010. TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy. Roum. Arch. Microbiol. Immunol. 69: 24-34.
19. Pakker NG, et al. 1998. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat. Med. 4:208-214. (Pubitemid 28137376)
20. Peruzzi M, Azzari C, Galli L, Vierucci A, De Martino M. 2002. Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clin. Exp. Immunol. 128:365-371. (Pubitemid 34534054)
21. Pontesilli O, et al. 1999. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol. Lett. 66:213-217. (Pubitemid 29136841)
22. + T cell activation during HIV infection. Nat. Med. 16:452-459.
23. Sondergaard SR, et al. 1999. Immune function and phenotype before and after highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 21:376-383. (Pubitemid 29383999)
24. Trabattoni D, et al. 2003. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101:2514-2520. (Pubitemid 36857606)
25. + T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-1202. (Pubitemid 44527357)
26. Velu V, et al. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458:206-210.
27. Wallet MA, et al. 2010. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 24:1281-1290.